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Background: A low muscle mass is prevalent in patients with metastatic colorectal cancer (mCRC) and has been
associated with poor treatment outcome. Chemotherapeutic treatment has an additional unfavorable effect on
muscle mass. Sufficient protein intake and physical activity are known to induce muscle protein anabolism in
healthy individuals, however it is unclear whether optimal nutrition is effective to preserve muscle mass in patients
with mCRC during first-line chemotherapy as well. We hypothesize that individual nutritional counseling by a
trained dietitian during first-line chemotherapy is effective in preserving muscle mass and may improve clinical
outcomes in patients with mCRC.
Methods/Design: In this multi-center single-blind randomized controlled trial, patients with mCRC scheduled for
first-line combination chemotherapy consisting of oxaliplatin and fluoropyrimidine, with or without bevacizumab
(n = 110), will be randomized to receive either individualized nutritional counseling by a trained dietitian to achieve
a sufficient dietary intake and an adequate physical activity level, or usual care. Outcome measures will be assessed
at baseline and after two and four months of treatment. The primary endpoint will be the change in skeletal muscle
area (measured by CT-scan) at the first treatment evaluation. Secondary endpoints will be quality of life, physical
functioning, treatment toxicity, treatment intensity and survival. Statistical analyses include one-sided t-tests for the
primary endpoint and mixed models and the Kaplan-Meier method for secondary endpoints.
Discussion: This randomized controlled trial will provide evidence whether individualized nutritional counseling
during chemotherapy is effective in preventing loss of muscle mass in patients with mCRC.
Trial registration: ClinicalTrials.gov NCT01998152; Netherlands Trial Register NTR4223.
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Colorectal cancer is the third most common cancer in
the world with nearly 1.4 million newly diagnosed pa-
tients in 2012 [1]. In 20% patients have metastatic dis-
ease at diagnosis and approximately 50% of the patients
develops metastatic disease (stage IV colorectal cancer)
[2]. For patients with disseminated disease for which
local treatment with curative intent is not possible, the
aim of treatment is to prolong survival with a good qual-
ity of life. Current combination treatment regimens of
chemotherapy and targeted agents result in a in a me-
dian survival up to 23–31 months [3-5].
Malnutrition and weight loss are common problems in
patients with metastatic colorectal cancer (mCRC) [6-8]:
the prevalence of any self-reported weight loss at presen-
tation varies from 34 to 72% [7,9] and 32% of the pa-
tients have lost more than 10% of their body weight at
presentation [8]. In addition to the loss of total body
weight, disproportionate loss of lean tissue weight is
common in patients with cancer [10]. A previous study
described a low muscle mass in 39% of the patients with
mCRC [8]. In our own institution we observed a low
muscle mass in 57% of the patients, while further loss of
muscle mass during treatment was present in more than
half of the patients (unpublished data), potentially due to
a decreased nutritional intake as a consequence of che-
motherapeutic toxicity [11]. In addition, physical activity
has shown to be decreased during treatment [12,13],
which could accelerate loss of muscle mass [14,15] and
is related to muscular deconditioning [16].
The relevance of muscle mass in patients with cancer
undergoing chemotherapy treatment has been described
in several studies. Observational studies show that an un-
favorable body composition with a low muscle mass is as-
sociated with reduced functional status [17] and quality of
life [18], more severe toxicity of treatment [19,20] and re-
duced survival [8,15,17,21,22]. A potential explanation for
a low muscle mass being an adverse prognostic factor is
that a low muscle mass reflects the increased metabolic
activity of a more aggressive tumor biology [22,23], al-
though the underlying mechanism explaining this associ-
ation has yet to be determined [22]. Another possibility is
that patients with a low muscle mass are more fragile and
susceptible to medical events [24], leading to a higher inci-
dence of chemotherapy-related toxicity [25] and to sub-
optimal treatment (delay, reduction or interruption of
chemotherapy) [24], both potential contributors to re-
duced survival [26]. In this case, clinical outcomes may be
improved by interventions aiming at preserving muscle
mass. For inducing muscle protein anabolism, a sufficient
protein intake, next to an adequete physical activity, is of
critical importance [14,27,28].
Only a few randomized controlled trials have been per-
formed to evaluate nutritional interventions in patientswith mCRC, none of them describing the effect of nutri-
tional intervention on muscle mass. One study suggested
that dietary advice had a beneficial effect on body weight
after one year, although patients with different types of tu-
mors were included and the numbers involved were small
(n = 68) [29]. Another randomized controlled trial was
ended prematurely because of crossover between the
intervention- and control arm [7]. A third study showed a
beneficial effect of parenteral nutriton compared to inten-
sive enteral nutrition on body mass index (BMI), body cell
mass, quality of life, chemotherapy-associated toxicity and
survival (n = 82), but there was no comparison to placebo
[30]. Due to absence of concrete evidence for a beneficial
effect of nutritional intervention on muscle mass and
treatment outcomes, there are no clear guidelines for nu-
tritional support in this selected population. This is the
main reason that additional nutritional support is not al-
ways provided [31].
We designed a randomized controlled trial to test our
hypothesis that individual nutritional counseling (NC)
by a trained dietitian during first-line chemotherapy is
effective in preserving muscle mass and thereby may im-
prove clinical outcome in patients with mCRC. The
main objective of the study is to determine whether NC
is effective in preserving muscle mass in patients with
mCRC during chemotherapy. In addition, treatment tox-
icity, quality of life and survival will be evaluated.
Methods
This single-blind multi-center randomized controlled
study will be performed by the Departments of Nutrition
and Dietetics and Medical Oncology of the VU University
Medical Center Amsterdam, The Netherlands. Patients
will be recruited from at least two Dutch hospitals (VU
University Medical Center, Amsterdam and Spaarne Hos-
pital, Hoofddorp), additional hospitals will be asked for
participation. Ethics approval has been obtained from the
Medical Ethical Committee of the VU University Medical
Center. This study will be conducted according to the
principles of the Declaration of Helsinki (64th version,
October 2013) and in accordance with the Medical Re-
search Involving Human Subjects Act (WMO, 1-3-2006).
Study population
Patients diagnosed with mCRC and scheduled for first-
line chemotherapy with capecitabine and oxaliplatin
(CAPOX) or infusional 5-fluorouracil and oxaliplatin
(FOLFOX), with or without bevacizumab (−B), will be
invited to enter the study. All patients should be over 18
years of age, have a World Health Organization (WHO)
performance score of 0–2, understand the Dutch lan-
guage and be able and willing to give written informed
consent. Exclusion criteria are chemotherapy in the pre-
vious three months and long-term use of high dose of
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nisolone or equivalent).
Once enrolled, the patient will be randomized to re-
ceive either individual NC by a trained dietitian (n = 55)
or usual nutritional care (UC, n = 55) during treatment
with CAPOX(−B) or FOLFOX(−B) (Figure 1). If chemo-
therapy is stopped prematurely, study participation will
also end. NC will be continued after study participation
when preferred by the patient (intervention group).
Randomization
Patients will be enrolled by a medical oncologist. The data
manager will randomize patients either to the intervention
group or the control group with use of randomization lists
generated by the statistician. Patients are randomized in
blocks of two and stratified for participating center,
type of chemotherapy and WHO performance score
(0/1 versus 2).
Blinding
The research assistant, who conducts the study visits and
performs the measurements, is blinded to the group as-
signment of the patients. Patients are requested to with-
hold their group assignment to the research assistant. Due
to the nature of the intervention, the treating dietitian, co-
ordinating researcher and participants cannot be blinded.
Skeletal muscle area measurement and data analyses will
be performed after blinding for treatment allocation.Figure 1 Study flowchart. mCRC: metastatic colorectal cancer.Intervention – nutritional counseling
Patients who have been assigned to the intervention group
will receive individualized NC by a trained dietitian, start-
ing at the first cycle of chemotherapy. The main goals of
the nutritional intervention will be to enable every patient
to achieve at least sufficient protein- and energy intake
with attention for sufficient intake of micronutrients and
an adequate physical activity level as described below.
NC is planned shortly before every treatment cycle,
with telephone reviews in between the face-to-face ses-
sions. Counseling consists of stimulating a sufficient
protein- and energy intake, based on the current ESPEN
(European society for clinical nutrition and metabolism)
guidelines for protein and energy [32]. The criterion for
sufficient protein intake is at least 1.2 grams per kg body
weight [33]. In patients with a BMI of >30 kg/m2,
protein requirements will be adjusted to a BMI of 27.5
kg/m2 [34]. Furthermore patients are advised to use at
least 25 grams of proteins per meal. This evenly distrib-
uted ingestion of protein throughout the day is expected
to maximally stimulate muscle protein synthesis [27].
Energy requirements are calculated based on the esti-
mated resting energy expenditure of Harris and Benedict
[35] plus an additional factor of 30% to correct for activ-
ity and disease.
To achieve a sufficient intake, an energy- and protein
enriched diet using regular food will be advised and easy
snack ideas and recipe suggestions will be provided. If a
Table 1 Outcome measures
Measurement Instrument Time point*
Primary outcome
Skeletal muscle area CT (skeletal muscle area L3) T0, T1
Secondary outcomes
Skeletal muscle area CT (skeletal muscle area L3) T0, T2
Quality of life EORTC QLQ C30 (global health-
and physical functioning domain)
T0, T1, T2
Hand grip strength Hydraulic hand dynamometer T0, T1, T2
Treatment toxicity Common Toxicity Criteria
version 4.0
ESP
Treatment intensity Dose index and time index of
chemotherapy
ESP
Adverse events Medical record ESP
Treatment response Response Evaluation Criteria




Medical record or general
practitioner office
After 2 years
*T0: prior to chemotherapy; T1: after three cycles of CAPOX(−B) or four cycles
of FOLFOX(−B); T2: after six cycles of CAPOX(−B) or eight cycles of FOLFOX
(−B); ESP: entire study period.
CT: Computed Tomography; EORTC QLQ: The European Organisation for
Research and Treatment of Cancer: Quality of life questionnaire. L3: third
lumbar vertebra.
van der Werf et al. BMC Cancer  (2015) 15:98 Page 4 of 7patient is unable to meet the dietary recommendations
(less than 75% of energy- and/or protein needs) and/or
loses body weight of ≥1 kg during a chemotherapy cycle,
energy- and protein enriched oral nutritional supple-
ments will be provided. If the body weight continues to
decrease or if nutritional goals cannot be met in spite of
oral nutritional supplements, tube feeding is indicated.
In addition to nutritional counseling, the dietitian will
encourage patients to achieve a physical activity level ac-
cording to the Dutch Healthy Exercise norm: at least
half an hour of moderately intensive physical activity
(e.g. walking, cycling or swimming) on at least five days
per week.
Control – usual nutritional care
Patients in the control-arm will receive UC: the medical
oncologist observes on a regular base at the outpatient
clinic and determines the patient’s tolerance, intake, condi-
tion and body weight as usual. When the medical oncolo-
gist concludes referral to a dietitian is indicated – for
instance in case of severe weight loss or insufficient dietary
intake – a dietitian will be consulted in agreement with
the patient.
Assessments
Outcomes will be assessed at study visits prior to
chemotherapy (baseline, T0) and after three cycles of
CAPOX(-B) (±9 weeks) or four cycles of FOLFOX(-B)
(±8 weeks) (T1), when therapy response is evaluated by
CT-scan. When chemotherapy is continued after T1,
study outcomes will also be assessed after six cycles of
CAPOX(-B) (±18 weeks) or eight cycles of FOLFOX(-B)
(±16 weeks) (T2). If chemotherapy is stopped or
switched to another chemotherapeutic drug after T1, T1
measures – among which the primary study endpoint –
will be completed and study participation will be ended.
Figure 1 shows a study flowchart and Table 1 gives an
overview of all outcome measures.
Patient and treatment characteristics
Demographic variables like age, gender and living situation
will be obtained from the medical record and a baseline
questionnaire. Medical data include comorbidity (using the
Charlson Comorbidity Index [36]), co-medication and
WHO performance score and will be extracted from med-
ical records.
Primary outcome
The primary endpoint will be the difference in change in
skeletal muscle area during the first three cycles of
CAPOX(−B) or four cycles of FOLFOX(−B) between the
intervention- and the control group. Baseline computed
tomography (CT)-scans (made within 30 days before
start of chemotherapy) will be compared to CT-scans atT1 to determine change in skeletal muscle area, using
routinely conducted CT-scans for diagnostic and disease
evaluation purposes. A trained, blinded person will
measure skeletal muscle area (cm2) with SliceOmatic
software V5.0 (Tomovision, Canada). The image at the
level of the third lumbar vertebra (L3) most clearly dis-
playing both vertebral transverse processes will be
chosen for measuring muscle area, since total cross sec-
tional skeletal muscle area at this level is highly corre-
lated with whole body skeletal muscle mass [37,38].
Slices of sequential CT-scans of one patient will be se-
lected at the same time using a split screen to ensure a
consistent location. Skeletal muscles at the level of L3
are identified based on anatomical features and quanti-
fied using Hounsfield units with thresholds for skeletal
muscle tissue from −29 to +150 [39]. The sum of all
these cross-sectional muscle areas (cm2) will be will be
computed by summing tissue pixels and multiplying by
the pixel surface area for each patient at each time
point.
Secondary outcomes
Secondary outcomes of this study will be (change in) the
following parameters between baseline (T0) and follow-up
(T1, T2), comparing the NC-group with the UC-group:
Change in skeletal muscle area after completion of
first-line chemotherapy If chemotherapy is continued
after three cycles of CAPOX(−B) or four cycles of
FOLFOX(−B), change in skeletal muscle area at L3 will
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CAPOX(−B) or eight cycles of FOLFOX(−B). In addition,
body composition will be estimated by bioelectrical im-
pedance at each study visit to assess the association with
change in muscle mass on CT-scan.
Quality of life The European Organization for Research
and Treatment of Cancer: Quality of life questionnaire
(EORTC QLQ-C30) will be used to assess quality of life
[40]. We have chosen to include the global health do-
main and the physical functioning domain as main items
in our quality of life analyses. The other items will be
analyzed in an explorative manner (including role-,
emotional-, cognitive- and social functioning, the symptom
scales, nausea and vomiting, pain, dyspnea, insomnia, loss
of appetite, constipation, diarrhea and financial difficulties).
Questionnaires will be scored according to the procedures
specified by the EORTC [41].
Hand grip strength Hand grip strength is an indicator
of overall muscle strength and is associated with func-
tional performance in advanced cancer patients [42,43].
Hand grip strength will be measured using a hydraulic
hand dynamometer (Baseline, Fabrication Enterprises,
USA) adjusted for the patient’s hand size. The test will
be performed sitting, with the shoulder adducted and
neutrally rotated, elbow flexed at 90 degrees, forearm
and wrist in neutral position. The highest value of two
maximal isometric contractions for each hand is re-
corded to the nearest kg. Measurements at different time
points will be compared to estimate changes in muscle
strength over time.
Treatment related outcomes Treatment related out-
comes include treatment toxicity, treatment intensity,
treatment outcome and survival. During the entire study
period, adverse events and treatment toxicity according
to the Common Toxicity Criteria version 4.0 [44] will be
monitored by the treating physician. Grade 3 to 5 tox-
icity when related to the treatment will be recorded as
adverse side effects from treatment. Adverse events and
serious adverse advents will be documented until study
participation is ended. Treatment intensity will be subdi-
vided in dose index (received cumulative dose/planned
cumulative dose) and time index (planned duration of
therapy/actual duration of therapy). Treatment outcome
will be evaluated at T1 and T2 with use of the Response
Evaluation Criteria In Solid Tumors (RECIST) [45] and
is defined as complete response, partial response, stable
disease and progressive disease. Furthermore, tumor
marker carcinoembryonic antigen (CEA; μg/l) will be
measured if initially elevated during routine blood sam-
pling at least once every six weeks. Progression free sur-
vival and overall survival will be evaluated.Other measures
Nutritional intake and physical activity Nutritional in-
take and physical activity will be assessed concurrently
during 3 days (one weekend- and two weekdays) at T0,
T1 and T2 to evaluate compliance to the intervention.
Patients are asked to keep a 3-day food diary to reli-
ably estimate nutritional intake [46]. During the study
visit, this diary will be comprehensively checked on
completeness by a trained and blinded research assistant.
Daily dietary energy- and macronutrient intake and dis-
tribution of protein throughout the day will be calcu-
lated by a nutrition analysis software application with
use of the most recent Dutch Food Composition table
(NEVO, RIVM, Bilthoven).
Physical activity will be estimated using a calibrated
physical activity monitor (PAM) accelerometer (model
AM200, PAM B.V., Doorwerth, The Netherlands). The
PAM scores physical activity based on acceleration and
duration of the activity. Accumulation of all PAM-points
during a day results in a PAM score, which indicates
daily physical activity and is a valid measure for habitual
physical activity [47].
Blood sampling In addition to CEA, inflammation
marker C-reactive protein will be measured during rou-
tine blood sampling at T0, T1 and T2. Furthermore, one
sample of stored serum and one sample of stored plasma
will be collected at T0 and T1 for future analysis on
serum proteins.
Sample size
Sample size calculations were made based on demon-
strating a decline in the proportion of patients showing
a clinically relevant decrease in skeletal muscle area of
6.0 cm2 (corresponding with approximately 1 kg loss of
skeletal muscle mass) [38,48]. To achieve 80% power
with a one-sided t-test for difference in proportions (α =
0.05), a sample size of 100 patients is required (assuming
a standard deviation of 9.5 cm2 and a mean decrease in
skeletal muscle area of 6.5 cm2 in the control arm and 0
cm2 in the intervention arm). A 10% buffer is added to
account for loss to follow-up before the clinical endpoint
can be assessed, resulting in a total sample size of 110
patients, 55 per study arm.
Statistical analysis
Data will be analyzed using SPSS (IBM Corp. Armonk,
NY) for descriptive- and statistical analyses. All analyses
will be performed according to the intention-to-treat
principle. For the primary outcome, one-sided t-tests for
difference in proportions will be performed to compare
the proportion of patients with a clinical relevant de-
crease in skeletal muscle area (6.0 cm2) between the
NC- and the UC-group. Difference in change in skeletal
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ent t-tests. For secondary outcomes, mixed effect models
will be used to evaluate change over time in dietary in-
take, physical activity, hand grip strength, quality of life
and treatment related outcomes and to examine differ-
ences between groups. Furthermore the association be-
tween dietary intake/physical activity and skeletal muscle
area will be assessed using regression models. Survival
probabilities will be estimated with the Kaplan-Meier
method.
Discussion
Malnutrition is a prevalent and underrecognized problem
in patients diagnosed with colorectal cancer. Of the pa-
tients with mCRC, 39-57% already has a low muscle mass
at diagnosis [8] and these patients are at risk of further
loss of muscle mass during chemotherapy. Observational
studies show that a low muscle mass is associated with an
adverse prognosis in patients with cancer. When poor out-
come is a consequence of a low muscle mass – possibly by
less treatment tolerance leading to suboptimal treatment
intensity and reduced survival – interventions aiming at
preserving muscle mass may improve clinical outcomes.
To date no randomized controlled trial has been per-
formed to study the effect of NC on muscle mass in pa-
tients with mCRC undergoing chemotherapy.
This study will determine the effect of NC (focused on
a sufficient dietary intake and an adequate physical activ-
ity level) on muscle mass during first-line chemotherapy.
The main objective is to evaluate whether NC can help
to preserve muscle mass. As secondary outcome mea-
sures, this study will also evaluate whether preservation
of muscle mass may improve the clinical outcomes such
as quality of life, physical functioning, treatment toxicity
and progression free survival.
The present study could provide an evidence based
support for the potential effect of NC. If this randomized
controlled trial demonstrates a beneficial effect of NC
on its primary outcome muscle mass in patients with
mCRC, NC should be evaluated in a subsequent phase 3
trial powered to determine whether it improves progres-
sion free and overall survival as well as quality of life.
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